{"id":104025,"date":"2026-06-09T21:35:47","date_gmt":"2026-06-09T21:35:47","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/104025\/"},"modified":"2026-06-09T21:35:47","modified_gmt":"2026-06-09T21:35:47","slug":"novo-nordisk-ceo-looks-beyond-weight-loss-to-longevity-aesthetics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/104025\/","title":{"rendered":"Novo Nordisk CEO Looks Beyond Weight Loss to Longevity, Aesthetics"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/NOVOB:DC\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Novo Nordisk A\/S<\/a> Chief Executive Officer Mike Doustdar says the company\u2019s blockbuster obesity drugs could ultimately pull it into increasingly buzzy areas of healthcare, from longevity research to aesthetic medicine.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">\u201cWe have to be obsessed with what our patients want,\u201d Doustdar said Sunday in an interview at the <a href=\"https:\/\/professional.diabetes.org\/scientific-sessions\" title=\"Link to Website\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">American Diabetes Association<\/a> conference in New Orleans. <\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S Chief Executive Officer Mike Doustdar says the company\u2019s blockbuster obesity drugs could ultimately pull it&hellip;\n","protected":false},"author":2,"featured_media":104026,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[53043,28414,726,691,16167,730,4003,13602,53042,14246,272,13578],"class_list":["post-104025","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-amer-diabetes-assoc","tag-c-suite","tag-chief-executive-officer","tag-drugs","tag-eli-lilly-co","tag-industries","tag-investing","tag-lars-rebien-sorensen","tag-maziar-mike-doustdar","tag-new-orleans","tag-novo-nordisk","tag-novo-nordisk-a-s-b"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116722304721045036","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/104025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=104025"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/104025\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/104026"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=104025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=104025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=104025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}